Development of dual and selective degraders of cyclin-dependent kinases 4 and 6

Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and CDK4/6 inhibitors are FDA-approved for treating patients with metastatic breast cancer. However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive. Here, we report i...

Full description

Saved in:
Bibliographic Details
Published in:Angew Chem Int Ed Engl
Main Authors: Jiang, Baishan, Wang, Eric S., Donovan, Katherine A., Liang, Yanke, Fischer, Eric S., Zhang, Tinghu, Gray, Nathanael S.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7678623/
https://ncbi.nlm.nih.gov/pubmed/30802347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.201901336
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items